Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 14/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230998 | 0.72 | MAOB (0.43) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL13361601 | 0.69 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL8365226 | 0.69 | SLC6A3 (0.44) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL14625430 | 0.67 | SLC6A3 (0.52) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL12691648 | 0.65 | MAOB (0.40) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL6925220 | 0.64 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL20743121 | 0.63 | SLC6A3 (0.42) | NPY5RSLC6A3SLC6A2SLC6A4CHRNA1 | |
| SCHEMBL21131147 | 0.63 | MAOB (0.43) | SLC6A3SLC6A2SLC6A4CHRNA1CHRNG | |
| SCHEMBL13097039 | 0.63 | OPRL1 (0.38) | NPY5RSLC6A3SLC6A2CHRNB2CHRNB4 | |
| SCHEMBL6926354 | 0.63 | OPRM1 (0.51) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160238-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55PHARMA DRUG DISCOVERY & DEVELOPMENT AG (AT) | 2011-06-30 | — | — | US | disclosed |
| EP-2315766-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55pharma Drug Discovery & Development AG (AT) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266967-A1 | Intermediates for the preparation of octahydroquinolizines | 55pharma Drug Discovery & Development AG (AT) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010144937-A2 | INTERMEDIATES FOR THE PREPARATION OF OCTAHYDROQUINOLIZINES | 55PHARMA DRUG DISCOVERY & DEVELOPMENT AG (AT) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010022412-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | 55PHARMA DRUG DISCOVERY & DEVELOPMENT AG (AT) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160238-A1 | OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT | SLC5A2, GPR119, ZYX | NPY5R 29/4885SLC6A3 1094/4885SLC6A2 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.